U037 Caring Beyond Cure: Palliative Care in Dermatology Practice
DESCRIPTION
Dermatology and palliative care are rarely mentioned together despite the fields’ shared focus on symptom management and quality of life. This session will introduce palliative care frameworks for dermatologists. Through cases, we will discuss how to deliver bad news, how to engage in multidisciplinary care and with patients’ caregivers, how to assess patients’ goals of care, how to assess symptomatology, and how to effectively manage pain and pruritus in patients with chronic, severe dermatologic conditions. The goal of this session is to provide dermatologists with tangible skills adapted from palliative care to provide effective, patient-focused care in fast-paced dermatology clinics.
LEARNING OBJECTIVES
Apply palliative care principles to dermatologic patients (frameworks for delivering bad news, assessing goals of care, and shared decision making)
Identify and effectively manage symptoms, such as pruritus and pain, in patients with severe, chronic dermatologic conditions or patients at end of life
DIRECTOR
Connie Zhong, MSc, MD, FAAD
University of Wisconsin-Madison
SPEAKERS
Rachel E. Meltzer, MD, MPH, FAAD
Brigham & Women's Hospital, Harvard Medical School
Lauren Orenstein, MD, FAAD
Emory University School of Medicine
DISCLOSURES
Rachel E. Meltzer, MD, MPH, FAAD
Apogee Therapeutics – Consultant (1099 relationship)(Honoraria), Stockholder Public Company(Stock); Galderma – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria); Veradermics – Advisory Board(Honoraria);
Lauren Orenstein, MD, FAAD
HS Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Advisory Board(Fees), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Advisory Board(Fees); Novartis – Advisory Board(Fees), Investigator(Grants/Research Funding); Phrase Health – Stockholder(Stock); UCB Pharma – Advisory Board(Fees);
Connie Zhong, MSc, MD, FAAD
No financial relationships exist with ineligible companies.